DRG 903 Overview

DRG 903 covers inpatient admissions for wound debridement procedures performed for injuries without Complication or Comorbidity or Major Complication or Comorbidity. Typical cases include surgical removal of necrotic or contaminated tissue from traumatic wounds when no additional coded complications are present. This Diagnosis-Related Group is important for Medicare payment because it groups these procedures into a single reimbursement category that affects hospital payment and resource classification. Accurate coding of the principal procedure and comorbidity status determines assignment to DRG 903.

Across commercial payers the observed rate range spans from about $370 up to $45K, with commercial means clustering between roughly $12K and $20K. Anthem shows the widest spread (min $390 to max $45K), as reflected in the table and chart below. Refer to the payer table and the benchmark chart for payer-specific quartiles and medians.

The CMS 2023 data represent national Medicare fee-for-service inpatient payments published under the CMS Provider Utilization and Payment Data program. The table below shows average total payment ($11.958k), average submitted covered charges ($56.820k), average Medicare payment ($9.347k), and total discharges (367).

• Acute procedural optimization studies: randomized or controlled trials evaluating different surgical debridement techniques, anesthesia approaches, or timing of debridement in hospitalized patients with traumatic or nontraumatic wounds requiring operative removal of necrotic tissue. These studies typically enroll adult inpatients who present with soft-tissue injuries, lacerations, or contaminated wounds without major comorbid complications (no CC/MCC) to determine which immediate intra‑hospital strategies reduce operative time, intraoperative blood loss, or need for repeat debridement. Results are directly relevant to surgeons, hospital administrators, and payers because optimized acute procedures can shorten length of stay, reduce resource utilization, and lower per‑episode costs while maintaining clinical safety.
• Comparative effectiveness research on adjunctive wound care modalities: prospective cohorts or randomized trials comparing adjuncts such as negative-pressure wound therapy, advanced dressings, enzymatic debriders, or topical agents used after initial operative debridement in patients without significant comorbid complications. These studies focus on the post‑operative in‑hospital and early post‑discharge phase to assess wound healing rates, time to secondary closure or grafting, infection rates, and need for readmission among relatively healthier injury patients. Findings inform clinicians and payers about which adjunctive therapies offer better healing trajectories or reduced downstream interventions—data that can influence device use policies, bundle payments, and discharge planning.
• Post-discharge outcomes and health services research: observational studies and registry analyses tracking functional outcomes, outpatient follow‑up adherence, wound-related readmissions, and rehabilitation needs for patients categorized under this DRG after hospital discharge. The population studied includes patients treated with debridement for injuries who did not have CC/MCC during the index stay; research questions include predictors of readmission, gaps in outpatient wound care access, and cost drivers in the 30–90 day post‑acute period. This area is important to providers and payers because it identifies opportunities to reduce avoidable readmissions, optimize transitional care pathways, and design targeted post‑discharge interventions that can improve outcomes and control total episode costs.